Prostate Cancer

Adding cabazitaxel to ADT and radiotherapy did not improve PFS or MFS vs SOC after 7 years among patients with high-risk localized prostate cancer.

Lutetium Lu 177 vipivotide tetraxetan–based therapy generated similar QOL outcomes compared with ADT plus an ARPI alone in patients with mHSPC.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The alpha-emitting radionuclide actinium-225 was well tolerated and produced PSA responses across all dose levels in patients with mCRPC.

Survey results highlight the top RCC and bladder cancer abstracts to watch at the 2026 Genitourinary Cancers Symposium.

Long-term follow-up data from PEACE-3 showed enzalutamide plus radium-223 improved OS and rPFS in patients with mCRPC and bone metastases.

Enrique Gallardo, MD, discusses final OS data from the phase 3 PEACE-3 trial of radium-223 with/without enzalutamide in mCRPC.

Stacy Loeb, MD, discusses findings from a study evaluating microplastics in prostate cancer tissue.

Short-course darolutamide boosted PSMA expression in some high-risk localized prostate cancer, supporting improved PSMA PET imaging strategies.

The addition of capivasertib to abiraterone elicited an rPFS advantage and preserved QOL compared with placebo plus abiraterone in PTEN-deficient mHSPC.

Abiraterone acetate, prednisone, and olaparib combination therapy boosted efficacy outcomes in first-line mCRPC.

Mehmet Bilen, MD, discusses considerations for treatment selection in mCSPC based on data from a real-world study of apalutamide vs darolutamide.

Mehmet Bilen, MD, discusses findings from a real-world analysis of apalutamide vs darolutamide in mCSPC.

The top 5 OncLive TV videos of the week cover insights in genitourinary cancers, hematologic malignancies, colorectal cancer, and sarcoma.

Mehmet Bilen, MD, discusses the rationale for a real-world analysis of apalutamide vs darolutamide in mCSPC.

Experts preview key bladder, kidney, and prostate cancer trials to watch at the 2026 Genitourinary Cancers Symposium.

At The University of Texas MD Anderson Cancer Center, research breakthroughs are made through collaboration between leading clinicians and scientists.

The FDA approves pembrolizumab regimen in select ovarian cancer, the agency clears Optune Pax for pancreatic cancer, and more this week.

The FDA has issued REMS safety updates regarding the use of the denosumab biosimilars Enoby and Ospomyv for patients with breast and prostate cancers.

Experts preview key prostate cancer abstracts to watch at the 2026 Genitourinary Cancers Symposium.

Mehmet Bilen, MD, discusses a retrospective analysis of patients receiving apalutamide vs darolutamide for metastatic castration-sensitive prostate cancer.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in January 2025 spanning tumor types.

Real-world, head-to-head data show an improvement in OS with apalutamide plus ADT vs darolutamide plus ADT without docetaxel in mCSPC.

EMA CHMP backs niraparib plus abiraterone with ADT for BRCA1/2-mutant mHSPC, supported by data from the AMPLITUDE study.

Mutahar Ahmed, MD, FACS, details the transvesical surgical approach for radical prostatectomy.